Gilead Sciences Inc
GILD124.700USD
-0.970-0.77%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
154.88BMarket Cap
19.15P/E TTM
More Details of Gilead Sciences Inc Company
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Gilead Sciences Inc Info
Ticker SymbolGILD
Company nameGilead Sciences Inc
IPO dateJan 22, 1992
CEOO'Day (Daniel P)
Number of employees17600
Security typeOrdinary Share
Fiscal year-endJan 22
Address333 Lakeside Dr
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404-1147
Phone16505743000
Websitehttps://www.gilead.com/
Ticker SymbolGILD
IPO dateJan 22, 1992
CEOO'Day (Daniel P)
Company Executives of Gilead Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
79.97K
-3.62%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Erin Burkhart
Ms. Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Senior Vice President, Principal Accounting Officer, Controller
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
79.97K
-3.62%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Erin Burkhart
Ms. Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Senior Vice President, Principal Accounting Officer, Controller
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
Biktarvy
3.53B
49.84%
Descovy
653.00M
9.22%
Yescarta
393.00M
5.55%
Genvoya
378.00M
5.34%
Trodelvy
364.00M
5.14%
Other
1.76B
24.91%
By RegionUSD
Name
Revenue
Proportion
United States
5.00B
70.59%
Europe
1.17B
16.51%
Other Locations
792.00M
11.18%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Biktarvy
3.53B
49.84%
Descovy
653.00M
9.22%
Yescarta
393.00M
5.55%
Genvoya
378.00M
5.34%
Trodelvy
364.00M
5.14%
Other
1.76B
24.91%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.54%
BlackRock Institutional Trust Company, N.A.
5.86%
State Street Investment Management (US)
4.76%
Fidelity Management & Research Company LLC
4.34%
Capital World Investors
3.64%
Other
71.86%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.54%
BlackRock Institutional Trust Company, N.A.
5.86%
State Street Investment Management (US)
4.76%
Fidelity Management & Research Company LLC
4.34%
Capital World Investors
3.64%
Other
71.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.42%
Investment Advisor/Hedge Fund
25.61%
Pension Fund
2.86%
Research Firm
2.81%
Hedge Fund
2.00%
Bank and Trust
1.90%
Sovereign Wealth Fund
1.73%
Insurance Company
0.15%
Venture Capital
0.10%
Other
8.41%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
3433
1.13B
91.16%
+23.58K
2025Q2
3388
1.12B
90.01%
-12.02M
2025Q1
3442
1.12B
90.14%
-10.49M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
118.78M
9.57%
+1.87M
+1.60%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
70.80M
5.71%
+138.89K
+0.20%
Jun 30, 2025
State Street Investment Management (US)
59.19M
4.77%
-335.51K
-0.56%
Jun 30, 2025
Fidelity Management & Research Company LLC
53.76M
4.33%
+2.55M
+4.98%
Jun 30, 2025
Capital World Investors
46.30M
3.73%
-7.24M
-13.53%
Jun 30, 2025
Dodge & Cox
30.82M
2.48%
-1.88M
-5.74%
Jun 30, 2025
Capital Research Global Investors
31.10M
2.51%
-23.51M
-43.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
29.21M
2.35%
+727.51K
+2.55%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
25.46M
2.05%
-89.95K
-0.35%
Aug 31, 2025
Wellington Management Company, LLP
37.53M
3.02%
+10.17M
+37.18%
Jun 30, 2025
View more
Related ETFs
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Name
Proportion
VanEck Biotech ETF
12.54%
ProShares Ultra Nasdaq Biotechnology
8.6%
Invesco Nasdaq Biotechnology ETF
8.54%
iShares Biotechnology ETF
7.24%
Simplify Health Care ETF
7.21%
Invesco Pharmaceuticals ETF
5.11%
Invesco Biotechnology & Genome ETF
5.08%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
4.62%
First Trust NASDAQ Pharmaceuticals ETF
4.12%
Tema Heart & Health ETF
3.95%
View more
VanEck Biotech ETF
Proportion12.54%
ProShares Ultra Nasdaq Biotechnology
Proportion8.6%
Invesco Nasdaq Biotechnology ETF
Proportion8.54%
iShares Biotechnology ETF
Proportion7.24%
Simplify Health Care ETF
Proportion7.21%
Invesco Pharmaceuticals ETF
Proportion5.11%
Invesco Biotechnology & Genome ETF
Proportion5.08%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
Proportion4.62%
First Trust NASDAQ Pharmaceuticals ETF
Proportion4.12%
Tema Heart & Health ETF
Proportion3.95%
Dividend
A total of
18.49B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 30, 2025
GILD.NB Final Cash Dividend of gross USD 0.79 paid on Dec 30, 2025 going ex on Dec 15, 2025
Dec 15, 2025
Dec 30, 2025
Dec 15, 2025
Aug 07, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Sep 29, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Sep 29, 2025
Sep 15, 2025
Apr 24, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Jun 27, 2025 going ex on Jun 13, 2025
Jun 13, 2025
Jun 27, 2025
Jun 13, 2025
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Gilead Sciences Inc?
The top five shareholders of Gilead Sciences Inc are:
The Vanguard Group, Inc. holds 118.78M shares, accounting for 9.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 70.80M shares, accounting for 5.71% of the total shares.
State Street Investment Management (US) holds 59.19M shares, accounting for 4.77% of the total shares.
Fidelity Management & Research Company LLC holds 53.76M shares, accounting for 4.33% of the total shares.
Capital World Investors holds 46.30M shares, accounting for 3.73% of the total shares.
The Vanguard Group, Inc. holds 118.78M shares, accounting for 9.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 70.80M shares, accounting for 5.71% of the total shares.
State Street Investment Management (US) holds 59.19M shares, accounting for 4.77% of the total shares.
Fidelity Management & Research Company LLC holds 53.76M shares, accounting for 4.33% of the total shares.
Capital World Investors holds 46.30M shares, accounting for 3.73% of the total shares.
What are the top three shareholder types of Gilead Sciences Inc?
The top three shareholder types of Gilead Sciences Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Gilead Sciences Inc (GILD)?
As of 2025Q3, 3433 institutions hold shares of Gilead Sciences Inc, with a combined market value of approximately 1.13B, accounting for 91.16% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.15%.
What is the biggest source of revenue for Gilead Sciences Inc?
In FY2025Q2, the Biktarvy business generated the highest revenue for Gilead Sciences Inc, amounting to 3.53B and accounting for 49.84% of total revenue.
